Prosecution Insights
Last updated: May 29, 2026
Application No. 16/627,396

METHOD FOR PRODUCING ERYTHROID PROGENITOR CELLS

Final Rejection §112
Filed
Dec 30, 2019
Priority
Jun 30, 2017 — FR 1756222 +1 more
Examiner
MOLOYE, TITILAYO
Art Unit
1632
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Univérsite Paris-Est-Crétéil Val De Marne
OA Round
6 (Final)
63%
Grant Probability
Moderate
7-8
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
338 granted / 533 resolved
+3.4% vs TC avg
Strong +47% interview lift
Without
With
+47.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
42 currently pending
Career history
581
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
56.9%
+16.9% vs TC avg
§102
5.8%
-34.2% vs TC avg
§112
19.7%
-20.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 533 resolved cases

Office Action

§112
DETAILED ACTION This action is in reply to papers filed 1/22/2026. Claims 41-45, 48-52, 54, 61 and 63-64 are pending with claims 41-45, 48-52, 61 and 63 are examined herein. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Examiner’s Note All paragraph numbers throughout this office action, unless otherwise noted, are from the US PGPub of this application US20200370015A1, Published 11/26/2020. Maintained Rejection(s) The 112 (b) rejection of claims 41-45, 48-52, 61 and 63 is maintained. Applicant’s arguments will be addressed following maintained rejection. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 41-45, 48-52, 61 and 63 remain rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 41 has been amended to recite "on day one of culture” in the last line. There is insufficient antecedent basis for this limitation in the claim. Note that there is no previous recitation of a culture period in the claim. Dependent claims 42-45, 48-52, 61 and 63 are included in this rejection as they fail to resolve the lack of antecedent basis issue of claim 41. Clarification is requested. Applicant’s Arguments/Response to Arguments Applicant argues: Amendments made to claim 41 render the issue of indefiniteness moot. In Response: Applicant’s arguments have been fully considered, but are not found persuasive. Note that Examiner previously indicated that claim 41 was rejected as being indefinite because there was no recitation of a culture period. Applicant’s amendment has not overcome this issue. In order to remedy this issue, Examiner suggests Applicant amend claim 41 such that the claim recites, inter alia, starting from the second line “…erythroid progenitors comprising culturing human hematopoietic stem cells in a cell culture..” or something similar. Because Applicant’s arguments were not found persuasive, the rejection is maintained. Authorization to Initiate Electronic Communications The examiner may not initiate communications via electronic mail unless and until applicants authorize such communications in writing within the official record of the patent application. See M.P.E.P. § 502.03, part II. If not already provided, Applicants may wish to consider supplying such written authorization in response to this Office action, as negotiations toward allowability are more easily conducted via e-mail than by facsimile transmission (the PTO's default electronic-communication method). A sample authorization is available at § 502.03, part II. Conclusion No claim is allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TITILAYO MOLOYE whose telephone number is (571)270-1094. The examiner can normally be reached Working Hours: 5:30 a.m-3:00 p.m. M-F. Off first Friday of biweek. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached on 571- 272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TITILAYO MOLOYE/ Primary Examiner, Art Unit 1632
Read full office action

Prosecution Timeline

Show 6 earlier events
Nov 21, 2024
Non-Final Rejection mailed — §112
May 21, 2025
Response Filed
Jun 17, 2025
Final Rejection mailed — §112
Nov 17, 2025
Request for Continued Examination
Nov 18, 2025
Response after Non-Final Action
Dec 01, 2025
Non-Final Rejection mailed — §112
Jan 22, 2026
Response Filed
Mar 31, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12630804
BLOOD BRAIN BARRIER MODEL
7y 3m to grant Granted May 19, 2026
Patent 12619211
METHOD AND APPARATUS FOR A TISSUE ENGINEERING SYSTEM UTILIZING STACKED LAYERS
4y 11m to grant Granted May 05, 2026
Patent 12618054
CRISPR/CPF1 SYSTEMS AND METHODS
4y 8m to grant Granted May 05, 2026
Patent 12611430
THERAPEUTIC AGENT OF PERIPHERAL BLOOD FLOW DISORDER
4y 11m to grant Granted Apr 28, 2026
Patent 12606834
METHODS AND COMPOSITIONS FOR EFFICIENT DELIVERY OF NUCLEIC ACIDS AND RNA-BASED ANTIMICROBIALS
4y 7m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+47.1%)
3y 7m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 533 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month